Home › Therapeutic areas › Immunology › Systemic Sclerosis

Systemic Sclerosis (12 companies)

Companies with an active program in Systemic Sclerosis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $256M 10
CABA Cabaletta Bio DermatologyImmunology+2 Rare 2 Phase 2 $220M 8
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 2 Phase 1 $249M 9
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 1 Phase 2 $13.2M 4
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $124M 10
LQDA Liquidia CardiovascularImmunology+1 Rare 1 Approved $5.11B 9
NKTX Nkarta ImmunologyNeurology+1 Rare 1 Phase 1 $89.6M 8
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 1 Phase 2 $236M 4
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $83.2M 5
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 $99.7M 4